Provided by Tiger Fintech (Singapore) Pte. Ltd.

Weight Loss Drugs

1,289.82
+40.123.21%
Number of Gainers:5
Number of Losers:2
Number of Flat:- -
PE:- -
High:1,301.32
Open:1,249.67
Low:1,249.67
Close:1,249.70
Loading ...

Pfizer Inc - Expects $500 Million Savings From R&D Simplification by 2026 - SEC Filing

THOMSON REUTERS
·
29 Apr

Hims & Hers Stock Soars 45%. Why a Deal With Novo Nordisk for Weight-Loss Drugs Matters. -- Barrons.com

Dow Jones
·
29 Apr

If You'd Invested $10,000 in Pfizer Stock 10 Years Ago, Here's How Much You'd Have Today

Motley Fool
·
29 Apr

Novo Nordisk Partners With Hims to Sell Wegovy at Reduced Price, Bloomberg Reports

MT Newswires Live
·
29 Apr

BRIEF-Pfizer Says Focused On Mitigating Opportunities In Near & Longer Term Regarding Potential Future Changes In Trade And Tariff

Reuters
·
29 Apr

BRIEF-Pfizer Reports First-Quarter 2025 Results

Reuters
·
29 Apr

BUZZ-Pfizer rises after quarterly profit beat, maintains 2025 forecast

Reuters
·
29 Apr

Pfizer: Current guidance assumes no share repurchases in 2025

TIPRANKS
·
29 Apr

Pfizer: Going Forward, Committed to Building Cardiometabolic Pipeline, Including in Obesity - Prepared Remarks

THOMSON REUTERS
·
29 Apr

Pfizer: Focused on Mitigating Opportunities in Near & Longer Term Regarding Potential Future Changes in Trade and Tariff Policies - Prepared Remarks

THOMSON REUTERS
·
29 Apr

Pfizer: in Total, Expect About $7.7 Bln in Savings by the End of 2027 to Drive Operating Efficiency

THOMSON REUTERS
·
29 Apr

Pfizer - Assessing Actions Including Potential Production of Certain API & Products in U.S. -Prepared Remarks

THOMSON REUTERS
·
29 Apr

Pfizer - Assessing Actions Like Management of Current Inventory Levels in Some Jurisdictions, Leveraging Domestic Manufacturing Footprint

THOMSON REUTERS
·
29 Apr

Pfizer: Currently Trending Towards Upper End of Our 2025 Adjusted Diluted EPS Guidance Range

THOMSON REUTERS
·
29 Apr

Pfizer Reports Solid First-Quarter 2025 Results and Reaffirms 2025 Guidance

THOMSON REUTERS
·
29 Apr

Pfizer: on Track to Exceed Net Cost Savings Targets

THOMSON REUTERS
·
29 Apr

Pfizer: No Share Repurchases Have Been Completed to Date in 2025

THOMSON REUTERS
·
29 Apr

Pfizer: Current Financial Guidance Does Not Anticipate Any Share Repurchases in 2025

THOMSON REUTERS
·
29 Apr

Pfizer Inc - Additional $1.2 Bln Cost Savings Expected by End 2027

THOMSON REUTERS
·
29 Apr

Pfizer Q1 Net Income USD 2,967 Million

THOMSON REUTERS
·
29 Apr